Evidence map›Paper›PMID 30171198›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.

Meredith Stevers, Joseph T Rabban, Karuna Garg, Jessica Van Ziffle, Courtney Onodera, James P Grenert, Iwei Yeh, Boris C Bastian, Charles Zaloudek, David A Solomon

Open access · bronzeAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Cellular Plasticity in Malignant Transformation: Mesothelial Cells.Pathobiology : journal of immunopathology, molecular and cellular biology · 2026
    Review
  3. Article
  4. Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Review
  5. Review
  6. Review
  7. Prognostic Role of L1CAM in Endometrial Cancer.Diagnostics (Basel, Switzerland) · 2025
    Review
  8. Article
  9. TheMicrobiology spectrum · 2024
    Article
  10. Article
  11. Article
  12. Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years.Virchows Archiv : an international journal of pathology · 2023
    Article
  13. Very Rare Peritoneal Surface Malignancies.Indian journal of surgical oncology · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Solid papillary mesothelial tumor.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Meredith SteversDepartment of Pathology, University of California, San Francisco, CA, USA.
Joseph T RabbanDepartment of Pathology, University of California, San Francisco, CA, USA.
Karuna GargDepartment of Pathology, University of California, San Francisco, CA, USA.
Jessica Van ZiffleDepartment of Pathology, University of California, San Francisco, CA, USA.
Courtney OnoderaClinical Cancer Genomics Laboratory, University of California, San Francisco, CA, USA.
James P GrenertDepartment of Pathology, University of California, San Francisco, CA, USA.
Iwei YehDepartment of Pathology, University of California, San Francisco, CA, USA.
Boris C BastianDepartment of Pathology, University of California, San Francisco, CA, USA.
Charles ZaloudekDepartment of Pathology, University of California, San Francisco, CA, USA.
David A SolomonDepartment of Pathology, University of California, San Francisco, CA, USA. david.solomon@ucsf.edu.ORCID http://orcid.org/0000-0003-4571-7999
University of California, San Francisco · US

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
Molecular and immunologic evolution of melanomas from pre-neoplastic lesionsR35CA220481 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BASTIAN, BORIS C. · 2017 to 2023
$6.3M
Cohesin gene mutations in tumorigenesisDP5OD021403 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SOLOMON, DAVID A. · 2015 to 2019
$2.0M
NCI NIH HHS P50 CA097257NCI NIH HHS R35 CA220481NIH HHS DP5 OD021403U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R35 CA220481U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD) DP5 OD021403
6 · The paper itself

Abstract

Well-differentiated papillary mesothelioma is an uncommon mesothelial neoplasm that most frequently arises in the peritoneal cavity of women of reproductive age. Whereas malignant mesothelioma is an aggressive tumor associated with poor outcome, well-differentiated papillary mesothelioma typically exhibits indolent behavior. However, histologically differentiating between these two entities can be challenging, necessitating the development of distinguishing biomarkers. While the genetic alterations that drive malignant mesothelioma have recently been determined, the molecular pathogenesis of well-differentiated papillary mesothelioma is unknown. Here we performed genomic profiling on a cohort of ten well-differentiated papillary mesothelioma of the peritoneum. We identified that all tumors harbored somatic missense mutations in either the TRAF7 or CDC42 genes, and lacked alterations involving BAP1, NF2, CDKN2A, DDX3X, SETD2, and ALK that are frequent in malignant mesothelioma. We recently identified that another mesothelial neoplasm, adenomatoid tumor of the genital tract, is genetically defined by somatic missense mutations in the TRAF7 gene, indicating a shared molecular pathogenesis between well-differentiated papillary mesothelioma and adenomatoid tumors. To the best of our knowledge, well-differentiated papillary mesothelioma is the first human tumor type found to harbor recurrent mutations in the CDC42 gene, which encodes a Rho family GTPase. Immunohistochemistry demonstrated intact BAP1 expression in all cases of well-differentiated papillary mesothelioma, indicating that this is a reliable marker for distinguishing well-differentiated papillary mesothelioma from malignant mesotheliomas that frequently display loss of expression. Additionally, all well-differentiated papillary mesothelioma demonstrated robust expression of L1 cell adhesion molecule (L1CAM), a marker of NF-kB pathway activation, similar to that observed in adenomatoid tumors. In contrast, we have previously shown that L1CAM staining is not observed in normal mesothelial cells and malignant mesotheliomas of the peritoneum. Together, these studies demonstrate that well-differentiated papillary mesothelioma is genetically defined by mutually exclusive mutations in TRAF7 and CDC42 that molecularly distinguish this entity from malignant mesothelioma.

Indexed as

AgedAged, 80 and overcdc42 GTP-Binding ProteinFemaleHumansMaleMesotheliomaMiddle AgedMutationPeritoneal NeoplasmsTumor Necrosis Factor Receptor-Associated Peptides and Proteinscdc42 GTP-Binding ProteinCDC42 protein, humanTRAF7 protein, humanTumor Necrosis Factor Receptor-Associated Peptides and Proteins

Identifiers

PMID30171198
PMCPMC6309365
OpenAlexW2889271032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.